Literature DB >> 9792649

Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling.

T L Born1, E Thomassen, T A Bird, J E Sims.   

Abstract

We have identified a novel member of the interleukin-1 (IL-1) receptor family, which we have termed AcPL. In transient transfection assays, we were unable to demonstrate a role for AcPL in IL-1-induced activation of NFkappaB. Interleukin-18 (interferon-gamma-inducing factor) is another member of the IL-1 family of cytokines, and it has recently been shown that IL-18 has a weak affinity for IL-1R-rp1. We examined whether AcPL might function alone or in concert with IL-1R-rp1 to mediate IL-18 signaling. We found that both IL-1R-rp1 and AcPL expression were required for induction of NFkappaB activity and for activation of c-Jun N-terminal kinase in response to IL-18. Furthermore, a dominant negative version of AcPL specifically inhibited IL-18 signaling. In vitro immunoprecipitation assays demonstrated that AcPL alone was unable to bind IL-18 with any appreciable affinity. We propose that although IL-1R-rp1 binds the cytokine, IL-1R-rp1 and AcPL proteins are both required for IL-18 signaling, analogous to the requirement for both IL-1R and IL-1RAcP in IL-1-mediated responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792649     DOI: 10.1074/jbc.273.45.29445

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

Review 1.  Interleukin-18, rheumatoid arthritis, and tissue destruction.

Authors:  J M Dayer
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils.

Authors:  T Yoshimoto; H Tsutsui; K Tominaga; K Hoshino; H Okamura; S Akira; W E Paul; K Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 3.  Interleukin-18 as a potential target in inflammatory arthritis.

Authors:  J A Gracie
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

4.  Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis.

Authors:  Roni Nowarski; Ruaidhrí Jackson; Nicola Gagliani; Marcel R de Zoete; Noah W Palm; Will Bailis; Jun Siong Low; Christian C D Harman; Morven Graham; Eran Elinav; Richard A Flavell
Journal:  Cell       Date:  2015-12-03       Impact factor: 41.582

5.  CD27- CD4+ memory T cells define a differentiated memory population at both the functional and transcriptional levels.

Authors:  Asa Schiött; Malin Lindstedt; Bengt Johansson-Lindbom; Erwin Roggen; Carl A K Borrebaeck
Journal:  Immunology       Date:  2004-11       Impact factor: 7.397

Review 6.  T-cell activation in the intestinal mucosa.

Authors:  Dina Montufar-Solis; Tomas Garza; John R Klein
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

7.  Stimulatory and costimulatory effects of IL-18 directed to different small intestinal CD43 T cell subsets.

Authors:  Dina Montufar-Solis; Heuy-Ching Wang; John R Klein
Journal:  J Leukoc Biol       Date:  2007-08-16       Impact factor: 4.962

8.  Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency.

Authors:  Eric P Zorrilla; Manuel Sanchez-Alavez; Shuei Sugama; Molly Brennan; Rosette Fernandez; Tamas Bartfai; Bruno Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

Review 9.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

Review 10.  The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/signaling pathways exist in the brain?

Authors:  Herve Boutin; Ian Kimber; Nancy J Rothwell; Emmanuel Pinteaux
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.